PT  - JOURNAL ARTICLE
AU  - Shah, Zalak
AU  - Naung, Myo T.
AU  - Moser, Kara A.
AU  - Adams, Matthew
AU  - Buchwald, Andrea G.
AU  - Dwivedi, Ankit
AU  - Ouattara, Amed
AU  - Seydel, Karl B
AU  - Mathanga, Don P.
AU  - Barry, Alyssa E.
AU  - Serre, David
AU  - Laufer, Miriam K.
AU  - Silva, Joana C.
AU  - Takala-Harrison, Shannon
TI  - Whole-genome analysis of Malawian <em>Plasmodium falciparum</em> isolates identifies potential targets of allele-specific immunity to clinical malaria
AID  - 10.1101/2020.09.16.20196253
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.16.20196253
4099  - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20196253.short
4100  - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20196253.full
AB  - Individuals acquire immunity to clinical malaria after repeated Plasmodium falciparum infections. This immunity to disease is thought to reflect the acquisition of a repertoire of responses to multiple alleles in diverse parasite antigens. In previous studies, we identified polymorphic sites within individual antigens that are associated with parasite immune evasion by examining antigen allele dynamics in individuals followed longitudinally. Here we expand this approach by analyzing genome-wide polymorphisms using whole genome sequence data from 140 parasite isolates representing malaria cases from a longitudinal study in Malawi and identify 25 genes that encode likely targets of naturally acquired immunity and that should be further characterized for their potential as vaccine candidates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the following awards granted by the National Institutes of Health: R01AI101713, R01AI125579, R01AI141900, U19AI110820, K24AI114996, and the Malawi International Center of Excellence for Malaria Research U19AI089683.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were collected under protocols approved by the ethics committees at the College of Medicine in Blantyre, Malawi, and the University of Maryland, Baltimore, and with the informed consent of the participants or their guardians.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available at NCBI under the project numbers and accession numbers listed in Supplementary Table 6 of the manuscript.